Bloomberg News

Celgene May Bid for Human Genome, Reuters Says

July 08, 2012

(Corrects to say second bidder will propose merger of equals in second paragraph)

Celgene Corp. (CELG:US) is one of two companies other than GlaxoSmithKline Plc (GSK) weighing a bid for Human Genome Sciences Inc., Reuters says, citing a source familiar with the situation that it didn’t identify.

A second unidentified bidder would propose a merger of equals, Reuters said yesterday. Glaxo has offered to buy Human Genome for $13 a share, and the U.S. biotechnology company has set a July 16 deadline for competing bids.

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editor responsible for this story: Dick Schumacher at dschumacher@bloomberg.net


Burger King's Young Buns
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • CELG
    (Celgene Corp)
    • $87.64 USD
    • 0.48
    • 0.55%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus